Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Diflunisal on Familial Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 75 years~* Biopsy proven amyloidosis~* Genotyping of variant transthyretin~* Signs of peripheral or autonomic neuropathy~Exclusion Criteria:~* Use of other non-steroidal anti-inflammatory drugs~* Other causes of sensorimotor polyneuropathy~* Anticipated survival \<2 years or liver transplantation in \<1 yr~* Liver transplantation~* Profound nerve, heart or kidney impairment~* Pregnancy or unwillingness to use contraception by women of childbearing age~* Active or recent gastrointestinal bleeding~* Non-steroidal or aspirin drug allergy/hypersensitivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Diflunisal (Type: ACTIVE_COMPARATOR): Diflunisal 250 mg po bid
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 po bid

Based on this trial design, predict the completion outcome and termination type (if applicable).